Vaccines against intracellular bacterial pathogens

Drug Discovery Today

Volumn 13, Issue 13-14, 2008, Pages 596-600

  Titball, Richard W ^a  

^a UNIVERSITY OF EXETER   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

VACCINE;

ANTIBODY RESPONSE; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CELLULAR IMMUNITY; DRUG RESEARCH; HUMORAL IMMUNITY; IMMUNE RESPONSE; IMMUNOGENICITY; REVIEW;

BACTERIAL INFECTIONS; BACTERIAL VACCINES; DRUG DESIGN; EXTRACELLULAR SPACE; GENOMICS; HUMANS; IMMUNITY; INTRACELLULAR SPACE; PROTEOMICS;

EID: 45849094397     PISSN: 13596446     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.drudis.2008.04.010     Document Type: Review

References (53)

1. th edn (2004), Saunders 1-16
2. th edn (2004), Saunders 959-987
3. th edn (2004), Saunders 589-624
4. th edn (2004), Saunders 529-588
5. Smith J.W. Diphtheria and tetanus toxoids. Br. Med. Bull. 25 (1969) 177-182
6. Grabenstein J.D. Vaccines: countering anthrax: vaccines and immunoglobulins. Clin. Infect. Dis. 46 (2008) 129-136
7. Hewlett E.L. Preparation and composition of acellular pertussis vaccines. Consideration of potential effects on vaccine efficacy. Dev. Biol. Stand. 89 (1997) 143-151
8. Goldschneider I., et al. Human immunity to the meningococcus. I. The role of humoral antibodies. J. Exp. Med. 129 (1969) 1307-1326
9. Borrow R., et al. Meningococcal surrogates of protection-serum bactericidal antibody activity. Vaccine 23 (2005) 2222-2227
10. Gordon S.B., et al. Intracellular trafficking and killing of Streptococcus pneumoniae by human alveolar macrophages are influenced by opsonins. Infect. Immun. 68 (2000) 2286-2293
11. th edn (2004), Saunders 229-268
12. Casadevall A., and Pirofski L.A. A reappraisal of humoral immunity based on mechanisms of antibody-mediated protection against intracellular pathogens. Adv. Immunol. 91 (2006) 1-44
13. Casadevall A. Antibody-mediated protection against intracellular pathogens. Trends Microbiol. 6 (1998) 102-107
14. Fulop M., et al. Role of antibody to lipopolysaccharide in protection against low- and high-virulence strains of Francisella tularensis. Vaccine 19 (2001) 4465-4472
15. Jones S.M., et al. Passive protection against Burkholderia pseudomallei infection in mice by monoclonal antibodies against capsular polysaccharide, lipopolysaccharide or proteins. J. Med. Microbiol. 51 (2002) 1055-1062
16. Nelson M., et al. Evaluation of lipopolysaccharide and capsular polysaccharide as subunit vaccines against experimental melioidosis. J. Med. Microbiol. 53 (2004) 1177-1182
17. Moore T., et al. Fc receptor-mediated antibody regulation of T cell immunity against intracellular pathogens. J. Infect. Dis. 188 (2003) 617-624
18. Igietseme J.U., et al. Antibody regulation of T cell immunity: implications for vaccine strategies against intracellular pathogens. Expert Rev. Vaccines 3 (2004) 23-34
19. Seder R.A., and Hill A.V. Vaccines against intracellular infections requiring cellular immunity. Nature 406 (2000) 793-798
20. + T cells specific for a single nonamer epitope of Listeria monocytogenes are protective in vivo. J. Exp. Med. 175 (1992) 1531-1538
21. Yingst S., and Hoover D.L. T cell immunity to brucellosis. Crit. Rev. Microbiol. 29 (2003) 313-331
22. Cassataro J., et al. A DNA vaccine coding for the Brucella outer membrane protein 31 confers protection against B. melitensis and B. ovis infection by eliciting a specific cytotoxic response. Infect. Immun. 73 (2005) 6537-6546
23. Kaufmann S.H. Protection against tuberculosis: cytokines, T cells, and macrophages. Ann. Rheum. Dis. 61 Suppl. 2 (2002) ii54-ii58
24. Moser B., and Eberl M. Gammadelta T cells: novel initiators of adaptive immunity. Immunol. Rev. 215 (2007) 89-102
25. Cao W., and He W. The recognition pattern of gammadelta T cells. Front. Biosci. 10 (2005) 2676-2700
26. Dudal S., et al. Release of LL-37 by activated human Vgamma9Vdelta2 T cells: a microbicidal weapon against Brucella suis. J. Immunol. 177 (2006) 5533-5539
27. Hedges J.F., et al. Mucosal lymphatic-derived gammadelta T cells respond early to experimental Salmonella enterocolitis by increasing expression of IL-2R alpha. Cell. Immunol. 246 (2007) 8-16
28. Berndt A., et al. Circulating gamma delta T cells in response to Salmonella enterica serovar enteritidis exposure in chickens. Infect. Immun. 74 (2006) 3967-3978
29. Poquet Y., et al. Expansion of Vgamma9 Vdelta2 T cells is triggered by Francisella tularensis-derived phosphoantigens in tularemia but not after tularemia vaccination. Infect. Immun. 66 (1998) 2107-2114
30. Bonneville M., and Scotet E. Human Vgamma9Vdelta2 T cells: promising new leads for immunotherapy of infections and tumors. Curr. Opin. Immunol. 18 (2006) 539-546
31. Sztein M.B. Cell-mediated immunity and antibody responses elicited by attenuated Salmonella enterica Serovar Typhi strains used as live oral vaccines in humans. Clin. Infect. Dis. 45 Suppl. 1 (2007) S15-S19
32. Pozsgay V. Recent developments in synthetic oligosaccharide-based bacterial vaccines. Curr. Top. Med. Chem. 8 (2008) 126-140
33. Heit A., et al. Vaccine protocols for enhanced immunogenicity of exogenous antigens. Int. J. Med. Microbiol. 298 (2008) 27-32
34. Tacket C.O., et al. Safety of live oral Salmonella typhi vaccine strains with deletions in htrA and aroC aroD and immune response in humans. Infect. Immun. 65 (1997) 452-456
35. Luthy K.E., et al. Safety of live-virus vaccines for children with immune deficiency. J. Am. Acad. Nurse Pract. 18 (2006) 494-503
36. Casswall T.H., and Fischler B. Vaccination of the immunocompromised child. Expert Rev. Vaccines 4 (2005) 725-738
37. Rao N. Protecting travelers from typhoid fever. Infect. Control Hosp. Epidemiol. 12 (1991) 168-172
38. Fishman J.A. Smallpox and live-virus vaccination in transplant recipients. Am. J. Transplant. 3 (2003) 786-793
39. Zhou H., and Beaudet A.L. A new vector system with inducible E2a cell line for production of higher titer and safer adenoviral vectors. Virology 275 (2000) 348-357
40. Brockstedt D.G., et al. Killed but metabolically active microbes: a new vaccine paradigm for eliciting effector T cell responses and protective immunity. Nat. Med. 11 (2005) 853-860
41. Hauguel T.M., and Hackett C.J. Rationally designed vaccine adjuvants: separating efficacy from toxicity. Front. Biosci. 13 (2008) 2806-2813
42. Kwissa M., et al. The science of adjuvants. Expert Rev. Vaccines 6 (2007) 673-684
43. Schijns V.E., and Degen W.G. Vaccine immunopotentiators of the future. Clin. Pharmacol. Ther. 82 (2007) 750-755
44. Tacken P.J., et al. Dendritic-cell immunotherapy: from ex vivo loading to in vivo targeting. Nat. Rev. Immunol. 7 (2007) 790-802
45. Kamath A.T., et al. Protective anti-mycobacterial T cell responses through exquisite in vivo activation of vaccine-targeted dendritic cells. Eur. J. Immunol. (2008) [Epub ahead of print]
46. Masoud H. LPS-based conjugate vaccines composed of saccharide antigens of smooth-type Salmonella enteritidis and rough-type S. gallinarum 9R bound to bovine serum albumin. Scand. J. Infect. Dis. 39 (2007) 315-322
47. Winter A.J., et al. Effectiveness of natural and synthetic complexes of porin and O polysaccharide as vaccines against Brucella abortus in mice. Infect. Immun. 56 (1988) 2808-2817
48. Fugier E., et al. Virulence factors in brucellosis: implications for aetiopathogenesis and treatment. Expert Rev. Mol. Med. 9 (2007) 1-10
49. Barrow P.A. Salmonella infections: immune and non-immune protection with vaccines. Avian Pathol. 36 (2007) 1-13
50. Martin C. Tuberculosis vaccines: past, present and future. Curr. Opin. Pulm. Med. 12 (2006) 186-191
51. Rappuoli R. Reverse vaccinology. Curr. Opin. Microbiol. 3 (2000) 445-450
52. Masignani V., et al. Reverse vaccinology: a genome-based approach for vaccine development. Expert Opin. Biol. Ther. 2 (2002) 895-905
53. Adu-Bobie J., et al. Two years into reverse vaccinology. Vaccine 21 (2003) 605-610